Israel based biopharmaceutical company Madrigal Mental Care has unveiled novel nanotechnology to deliver psilocybin through nasal spray for treatment and prevention of post-traumatic stress disorder at Biomed Israel 2022 which took place at the InterContinental Hotel in Tel Aviv, Israel on May 10.
Biomed Israel is a wide celebration of the life science and technology sector in Israel, last year’s event attracted more than 6,000 attendees whereby 1,000 where international attendees from over 45 countries across the world.
The naval nose spray enables nose-to-brain delivery of organic nanoparticles which encapsulate molecules of psychedelic substances psilocybin in particular. The naval spray delivery system can also be used to deliver ketamine, MDMA, mescaline and other psychedelic compounds.
The nanotechnology was invented by Prof. Amnon Sintov who is a biomedical engineering professor at Ben-Gurion University of the Negev (BGU). The professor also has a license from the Technology Transfer Company of BGU, BGN Technologies.
“An increasing number of studies point to the advantages of using psychedelic drugs for the treatment of psychiatric disorders such as PTSD, depression, anxiety, obsessive compulsive disorder, and even addiction, with low doses. Due to their powerful effect on the human brain, it is imperative to be able to deliver these drugs in a safe manner and in precise doses. Our novel nanotechnology platform enables encapsulation of precise drug doses in nanoparticles that are delivered directly to the brain via an intranasal spray, in a very efficient, fast, and safe manner,” said Prof Sintov.
According to the company’s co-founder and Chairman, David Gabay, Vitro studies proved that psilocybin particles used in the nanoparticles have a beneficial effect on inflamed brain cells culture.
“Our technology ensures a focused and fast delivery of accurate doses of psychoactive substances. The nanoparticles are biodegradable and provide a significant advantage over common practices in terms of stability and accuracy. We are currently beginning preclinical trials with rodents with the aim of achieving efficacy and safety approvals in order to begin first-in-human clinical trials next year. We have great confidence that this novel technology will propel forward the field of psychedelic-based treatments, for the benefit of millions of people around the world coping with chronic and acute psychiatric conditions such as PTSD and depression,” said Gabay.